Login to Your Account

China's I-O race getting hotter as Mabspace closes $40M series B financing

By Shannon Ellis
Staff Writer

Wednesday, May 16, 2018

SHANGHAI – Chinese antibody discovery biotech Mabspace Biosciences Co. Ltd., of Suzhou, has raised $40 million in series B financing to further pursue its immuno-oncology (I-O) ambitions. Founded in 2013, the startup has proved itself to be relatively careful with money. Its last round of financing was three years ago, when Mabspace raised $15 million from Lilly Asia Ventures (an independent venture fund, once a part of Eli Lilly and Co.).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription